Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Aigen Investment Management LP

Aigen Investment Management LP raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,942 shares of the biopharmaceutical company’s stock after purchasing an additional 2,361 shares during the period. Aigen Investment Management LP’s holdings in Halozyme Therapeutics were worth $330,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of HALO. Advisors Asset Management Inc. raised its stake in Halozyme Therapeutics by 0.6% in the third quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock valued at $1,742,000 after buying an additional 287 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares during the last quarter. Truist Financial Corp boosted its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. Truist Financial Corp now owns 102,622 shares of the biopharmaceutical company’s stock valued at $3,793,000 after purchasing an additional 563 shares in the last quarter. Alliance Wealth Advisors LLC UT increased its stake in Halozyme Therapeutics by 7.4% in the third quarter. Alliance Wealth Advisors LLC UT now owns 8,389 shares of the biopharmaceutical company’s stock valued at $320,000 after purchasing an additional 581 shares during the last quarter. Finally, HighTower Advisors LLC raised its holdings in Halozyme Therapeutics by 3.2% during the third quarter. HighTower Advisors LLC now owns 18,988 shares of the biopharmaceutical company’s stock worth $725,000 after purchasing an additional 583 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded down $0.10 during midday trading on Friday, hitting $43.82. The company had a trading volume of 898,705 shares, compared to its average volume of 1,041,106. Halozyme Therapeutics, Inc. has a 52-week low of $31.86 and a 52-week high of $46.16. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The company’s 50 day simple moving average is $40.88 and its 200 day simple moving average is $38.84. The stock has a market cap of $5.58 billion, a price-to-earnings ratio of 18.11, a PEG ratio of 0.49 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.44 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $39.55, for a total transaction of $395,500.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,191,868.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 40,000 shares of company stock valued at $1,650,600 over the last quarter. Corporate insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on HALO. Benchmark restated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. JMP Securities dropped their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 8th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Wednesday. TD Cowen started coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 target price for the company. Finally, StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $53.14.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.